Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA

Neuropharmacology, Journal Year: 2021, Volume and Issue: 193, P. 108610 - 108610

Published: May 16, 2021

Language: Английский

---

Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(4), P. e0282396 - e0282396

Published: April 12, 2023

Legal Cannabis products in the United States are required to report THC potency (total % by dry weight) on packaging, however concerns have been raised that reported values inaccurate. Multiple studies demonstrated is a primary factor determining pricing for flower, so it has an outsized role marketplace. Reports of inflated and “lab shopping” obtain higher results circulating some time, but side-by-side investigation flower package not previously conducted. Using HPLC, we analyzed 23 samples from 10 dispensaries throughout Colorado Front Range compared packaging. Average observed was 14.98 +/- 2.23%, which substantially lower than recent reports summarizing dispensary potency. The average 23.1% lowest label 35.6% highest values. Overall, ~70% were more 15% numbers label, with three having only one half maximum Although exact source discrepancies difficult determine, lack standardized testing protocols, limited regulatory oversight, financial incentives market high likely play significant role. Given our urgent steps taken increase accuracy being sold public. accurate reporting can impacts medical patients controlling dosage, recreational consumers expecting effect aligned price, trust industry as whole. As legal cannabis continues grow, essential moves toward selling labeling.

Language: Английский

---

The role of stigma in cannabis use disclosure: an exploratory study

Harm Reduction Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: Jan. 26, 2024

Abstract Background Although cannabis use incidence, societal acceptance, and legislation all trend positively, remains federally illegal in the USA. Prior studies have revealed that patients are reluctant to disclose their history healthcare system, which can negatively impact patient care. This study reports frequency of disclosure with special considerations for stigmatization. To better understand limitations, providers face providing collaborative, comprehensive, informed care, this evaluated four domains stigma: perceived, anticipated, enacted, internalized. Methods used a descriptive exploratory design. Data collection occurred using an anonymous, online national survey convenience sample Recruitment relied on electronic media between July December 2022. Participants were adults older than 21 years self-identified as having accessed system within last five years. The measured demographic characteristics, use, patterns. Stigma was Use Mechanism Scale (SU-SMS) Substance Abuse Self-Stigma (SASSS) language modifications cannabis. Ordinal logistic regression models performed evaluate associations patterns each stigma category. Associations assessed Chi-squared or Fisher’s exact tests. Results available 249 respondents. Most participants (57.1%) reported initiating conversation about provider; 27.8% time, is never discussed, initiate only 15.1% related discussions. Anticipated [95% CI 1.045–1.164] total 1.001–1.039] had statistically significant nondisclosure. Annual household income ( p = .04), chronicity .03), .02), known amount CBD products consumed .01) disclosure. Conclusions Patients who experience stigmatization setting may limit history. Future would be well served explore anticipated more deeply. Healthcare should knowledgeable lead such conversations relating while maintaining unbiased perspective.

Language: Английский

---

Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis

Drug and Alcohol Dependence, Journal Year: 2024, Volume and Issue: 257, P. 111267 - 111267

Published: March 13, 2024

Language: Английский

---

The why behind the high: determinants of neurocognition during acute cannabis exposure

Nature reviews. Neuroscience, Journal Year: 2021, Volume and Issue: 22(7), P. 439 - 454

Published: May 27, 2021

Language: Английский

---

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: June 6, 2022

Background and aims: The effects exuded by cannabis are a result of the cannabinoids trans-Δ⁹-tetrahydrocannabinol (THC) cannabidiol (CBD), is dependent upon their pharmacological interaction linked to two cannabinoids' concentrations ratios. Based on current literature trends increasing potency, we postulate that most medical products with THC CBD have ratios capable producing significant acute intoxication similar recreational products. We will test this organizing into clinically distinct categories according TCH:CBD ratios, evaluating data in terms therapeutic potential, comparing obtained from programs states differing market policies. Methods: utilized encompassing online herbal dispensary product offerings nine U.S. states. were analyzed after being divided four THC:CBD ratio identified based literature: can enhance (THC:CBD ≥1:1), has no effect (ratios ∼ 1:2), either or mitigate 1:>2 < 6), protective against ≤1:6). Results: A number (58.5%) did not contain any information content. Across all sampled, majority (72-100%) both (>0%) fall intoxicating category (≥1:1 THC:CBD), likely enhancing THC's effects. least (1:>2 6 ≤1:6 THC:CBD) provided smallest Similarly, without (0%) contained highly potent amounts (>15%). These results consistent, regardless policies place. Conclusions: Despite goals users, program nearly identical. Patients seeking benefits therefore at substantial risk unwanted side effects, whether they obtain programs. Efforts needed better inform patients risks associated high potency between CBD, help shape promote more options.

Language: Английский

---

Cannabis retailer marketing strategies and regulatory compliance: A surveillance study of retailers in 5 US cities

Addictive Behaviors, Journal Year: 2023, Volume and Issue: 143, P. 107696 - 107696

Published: March 17, 2023

Language: Английский

---

Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021

Addictive Behaviors, Journal Year: 2023, Volume and Issue: 140, P. 107617 - 107617

Published: Jan. 9, 2023

Language: Английский

---

Driving under the influence of cannabis, alcohol, and illicit drugs among adults in the United States from 2016 to 2020

Addictive Behaviors, Journal Year: 2023, Volume and Issue: 140, P. 107614 - 107614

Published: Jan. 9, 2023

Language: Английский

---

How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?

Addiction, Journal Year: 2023, Volume and Issue: 118(6), P. 998 - 1003

Published: Jan. 20, 2023

An increased use of high-potency cannabis products since legalization in the United States, Canada and elsewhere may increase cannabis-related harm. Policymakers have good reasons for regulating more potent ways that minimize harm, using approaches similar to those used regulate alcohol; namely, banning sale cannabis, setting a cap on tetrahydrocannabinol (THC) content imposing higher rates taxes products. Given difficulty US policymakers had extracts edibles, governments are planning legalize need put policies into enabling legislation evaluate impact these harms.

Language: Английский

---